JPH046685B2 - - Google Patents
Info
- Publication number
- JPH046685B2 JPH046685B2 JP60189405A JP18940585A JPH046685B2 JP H046685 B2 JPH046685 B2 JP H046685B2 JP 60189405 A JP60189405 A JP 60189405A JP 18940585 A JP18940585 A JP 18940585A JP H046685 B2 JPH046685 B2 JP H046685B2
- Authority
- JP
- Japan
- Prior art keywords
- dietary fiber
- anemia
- fiber
- drug
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000013325 dietary fiber Nutrition 0.000 claims description 39
- 208000007502 anemia Diseases 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims description 10
- 235000021536 Sugar beet Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 description 13
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 244000247812 Amorphophallus rivieri Species 0.000 description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920002488 Hemicellulose Polymers 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000252 konjac Substances 0.000 description 3
- 235000010485 konjac Nutrition 0.000 description 3
- 229920005610 lignin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229960003893 phenacetin Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
（産業上の利用分野）
この発明は薬物の投与に起因して発現する貧血
の抑制剤に関するもので、更に詳しくは抑制物質
として無害な食物繊維を使用する点において特徴
を有する。
（従来の技術）
臨床において、貧血は最も多く遭遇する症状の
一つであつて、その原因は多岐にわたつている。
若し、その原因が鉄不足などの食事のかたよりに
よる栄養欠損である場合には必要な栄養素を含む
薬剤を投与するか、あるいは食事の改善により治
療することができる。しかしながら風邪薬フエナ
セチンなどの投薬の副作用として現われる薬物起
因性の貧血については、予防あるいは治療に対し
未だ的確な手段はない。
一方食物繊維には水溶性食物繊維、不溶性食物
繊維の別が存在し、それらが、肥満、動脈硬化、
心臓病、糖尿病、大腸ガン、直腸ガン等の所謂文
明病の治療に効果を有することは知られているが
食物繊維が貧血に効果があるとか、更には薬物起
因の貧血を抑制ないし阻止するなどということは
全く知られていない。
（発明が解決しようとする問題点）
薬物に起因する貧血は前記フエナセチンの例に
限らず各種疾病に対する投薬の際副作用として現
われる現象で、特に近年では増加しているが、こ
れに対し、無害にして有効な治療手段は確立して
おらず、その確立が強く要望されている。
（問題を解決するための手段）
この発明は上記の事情によりなされたもので、
この発明者らは無害な物質で薬物起因の貧血を抑
制ないし阻止せんと食物繊維に注目して研究を進
めた結果、水溶性食物繊維と不溶性食物繊維とを
含有する食物繊維を有効成分とする薬物起因の貧
血抑制剤の開発に成功したもので、該食物繊維と
して甜菜から調製された食物繊維、或は甜菜から
調製された食物繊維の中性消化画分を使用すると
大きい効果を奏するものである。
（作 用）
この発明に使用する食物繊維はヘミセルロー
ス、ペクチン、アルギン酸、寒天、マンナン、ガ
ム質等の水溶性食物繊維とセルロース、リグニン
等の不溶性食物繊維を含有するものであればよ
い。
次に、この発明を甜菜から調製した食物繊維の
例により説明する。該食物繊維は常法により糖分
を抽出後乾燥、粉砕、篩別して調製したものであ
る。又実験はラツトを使用し、予備試験により、
１，２−ジメチルヒドラジン（以下DMHと略記
することがある）をラツトに投与し貧血が誘発さ
れることを確認の上、５週令のラツト（雄、平均
体重140ｇ）10匹を１群とし、これを５群用意し
各種条件で飼育した。ラツトの飼育用基本飼料は
カゼイン25％、コーン油５％、ミネラル混合物４
％、ビタミン混合物１％、コリン塩酸塩0.2％、
ビタミンＥ顆粒0.1％、蔗糖64.7％とし、これに
前記甜菜繊維粉末（60〜200メツシユ）コンニヤ
ク粉末（60〜20メツシユ）及び木材セルロース粉
末（60〜200メツシユ）を、夫々蔗糖の一部に代
替しそれぞれ全体の10％となるように添加した３
種類の調整飼料を準備し、同一条件で18週間飼育
した。１，２−ジメチルヒドラジンは飼育開始時
とその後１週間ごとに計９回、１回につきラツト
体重１Kg当り30mgの割合で投与した。飼育終了
後、体重増、尾部静脈採血によるヘモクロビン
値、内臓重量を測定した。
その結果を第１表に示す。
(Industrial Application Field) The present invention relates to an agent for suppressing anemia caused by administration of a drug, and more specifically, it is characterized in that harmless dietary fiber is used as the suppressing substance. (Prior Art) Anemia is one of the most frequently encountered symptoms in clinical practice, and its causes are diverse.
If the cause is a nutritional deficiency due to poor diet, such as iron deficiency, it can be treated by administering drugs containing the necessary nutrients or by improving the diet. However, there is still no accurate means for preventing or treating drug-induced anemia that appears as a side effect of medications such as the cold medicine phenacetin. On the other hand, there are two types of dietary fiber: soluble dietary fiber and insoluble dietary fiber, which are associated with obesity, arteriosclerosis,
It is known that dietary fiber is effective in treating so-called civilized diseases such as heart disease, diabetes, colon cancer, and rectal cancer, but it is also said that dietary fiber is effective for anemia, and even suppresses or prevents drug-induced anemia. That is completely unknown. (Problems to be Solved by the Invention) Drug-induced anemia is a phenomenon that appears as a side effect when taking medication for various diseases, not just the example of phenacetin, and has been increasing particularly in recent years. No effective treatment method has been established, and its establishment is strongly desired. (Means for solving the problem) This invention was made due to the above circumstances,
The inventors conducted research focusing on dietary fiber in order to suppress or prevent drug-induced anemia with a harmless substance, and as a result, they discovered that the active ingredient is dietary fiber containing water-soluble dietary fiber and insoluble dietary fiber. A drug-induced anemia suppressant has been successfully developed, and the use of dietary fiber prepared from sugar beet, or a neutrally digested fraction of dietary fiber prepared from sugar beet, is highly effective. be. (Function) The dietary fibers used in this invention may be those containing water-soluble dietary fibers such as hemicellulose, pectin, alginic acid, agar, mannan, and gum, and insoluble dietary fibers such as cellulose and lignin. Next, this invention will be explained using an example of dietary fiber prepared from sugar beet. The dietary fiber is prepared by extracting the sugar content, followed by drying, crushing, and sieving in a conventional manner. In addition, the experiment used rats, and preliminary tests showed that
After confirming that 1,2-dimethylhydrazine (hereinafter sometimes abbreviated as DMH) was administered to rats to induce anemia, a group of 10 5-week-old male rats (average weight 140 g) was prepared. Five groups of these were prepared and reared under various conditions. The basic feed for rats is 25% casein, 5% corn oil, and 4% mineral mixture.
%, vitamin mixture 1%, choline hydrochloride 0.2%,
Vitamin E granules are 0.1% and sucrose is 64.7%, and the sugar beet fiber powder (60-200 mesh), konjac powder (60-20 mesh) and wood cellulose powder (60-200 mesh) are each substituted for part of the sucrose. 3 were added to each amount to 10% of the total.
Different types of prepared feed were prepared and reared under the same conditions for 18 weeks. 1,2-dimethylhydrazine was administered at a rate of 30 mg/kg of rat body weight a total of 9 times at the beginning of rearing and every week thereafter. After rearing, body weight gain, hemoglobin level by tail vein blood sampling, and visceral weight were measured. The results are shown in Table 1.
【表】
第１表より１，２−ジメチルヒドラジン投与に
よる貧血症状は明らかに認められ、基本飼料によ
る飼育で１，２−ジメチルヒドラジンを投与した
場合18週以前に10体中の死亡があり、体重は４％
減、ヘモグロビン値約31％減、肝臓重量約23％
減、脾臓重量は約21％増を示した。貧血はその個
体の全血液と全赤血球の絶対的減少であり、ヘモ
グロビン値の減少した状態である。又、肝臓の萎
縮、生長抑制は貧血に伴う二次的現象であり、脾
臓の肥大は種々の代謝性疾患によつて観察される
現象であるが特に貧血の疾患において顕著であ
る。脾臓の肥大と貧血は強い関連を持つた臨床的
現象である。調整飼料による飼育ではコンニヤク
粉調整飼料区と木材セルロース粉調整飼料区にあ
つては１，２−ジメチルヒドラジンを投与した基
本飼料区とほぼ同じ傾向を示し、甜菜繊維調整飼
料だけが１，２−ジメチルヒドラジンを投与した
基本飼料区の諸数値を改善しており、１，２−ジ
メチルヒドラジンを投与しない基本飼料区に比
べ、脾臓重量において高い他は、約20％以下の減
についており、18週以前に検体の死亡はなかつ
た。
この実験に用いた繊維はいずれも食物繊維とし
て知られるものであるが、この実験例から判明す
るようにその種類により、生体に及ぼす機能に差
のあることが示唆される。貧血抑制に効果しなか
つたコンニヤク粉末はグルコマンナンを基本構造
とする中性ヘテログルカンで水溶性の食物繊維に
属し、木材セルロース粉末はグルカンを基本構造
とするセルロースと５〜８％のリグニンを含有す
る水不溶性繊維に相当することから、水溶性又は
水不溶性の食物繊維単独では貧血を抑制する効果
は認められない。一方、貧血抑制に効果を示した
甜菜繊維はキシランを基本構造とすることが知ら
れるヘミセルロースとガラクツロナンを基本構造
とするペクチンからなる水溶性の食物繊維とグル
カンを基本構造とするセルロースと約３％のリグ
ニンを含有する水不溶性の食物繊維の両方を含む
このことから、貧血抑制に効果を有する食物繊維
は水溶性と水不溶性の食物繊維が同時に含まれて
いることが不可欠であることが認められる。
次いで甜菜繊維からVan Soestのdetergent
fiber法〔印南、桐山編食物繊維、p38−46 1982
年５月15日第一出版発行〕に準拠して中性消化繊
維（NDF）画分と酸性消化繊維（ADF）画分
を、また、綾野等の手法（栄養と食糧vol.35No.６
431−439 1982）に準拠してヘミセルロース画
分を夫々調製し、第１表に準じラツトの飼育を行
つた。この結果を第２表に示す。[Table] From Table 1, anemia symptoms due to administration of 1,2-dimethylhydrazine were clearly observed, and when 1,2-dimethylhydrazine was administered while being fed basic feed, 10 out of 10 animals died before 18 weeks. Weight is 4%
decreased, hemoglobin level decreased by approximately 31%, liver weight decreased by approximately 23%
The spleen weight increased by approximately 21%. Anemia is an absolute decrease in total blood and total red blood cells in the individual, and is a condition of decreased hemoglobin levels. Furthermore, atrophy and growth inhibition of the liver are secondary phenomena associated with anemia, and enlargement of the spleen is a phenomenon observed in various metabolic diseases, but is particularly noticeable in anemic diseases. Splenomegaly and anemia are clinical phenomena that are strongly related. In rearing with prepared feed, the konjac flour prepared feed group and the wood cellulose powder prepared feed group showed almost the same trends as the basic feed group administered with 1,2-dimethylhydrazine, and only the sugar beet fiber prepared feed showed 1,2- Various numerical values in the basic feed group administered with dimethylhydrazine have been improved, and compared to the basic feed group without administration of 1,2-dimethylhydrazine, the weight of the spleen is higher, but the reduction is about 20% or less, and after 18 weeks There were no previous deaths in the specimen. All of the fibers used in this experiment are known as dietary fibers, but as is clear from this experimental example, it is suggested that there are differences in the functions they exert on the living body depending on the type. Konjac powder, which was not effective in suppressing anemia, is a neutral heteroglucan whose basic structure is glucomannan and belongs to water-soluble dietary fiber, and wood cellulose powder contains cellulose whose basic structure is glucan and 5 to 8% lignin. Therefore, water-soluble or water-insoluble dietary fiber alone is not effective in suppressing anemia. On the other hand, sugar beet fiber, which has been shown to be effective in suppressing anemia, contains approximately 3% water-soluble dietary fiber consisting of hemicellulose, which is known to have xylan as its basic structure, pectin, which has galacturonan as its basic structure, and cellulose, which has glucan as its basic structure. From this fact, it is recognized that dietary fiber that is effective in suppressing anemia must contain both water-soluble and water-insoluble dietary fibers at the same time. . Then Van Soest detergent from sugar beet fiber
Fiber method [edited by Inami and Kiriyama, dietary fiber, p38-46 1982
Neutral digestible fiber (NDF) fraction and acidic digestible fiber (ADF) fraction were determined according to the method of Ayano et al. (Nutrition and Food Vol. 35 No. 6).
431-439 1982), and rats were raised according to Table 1. The results are shown in Table 2.
【表】
第２表の結果より水不溶性の繊維に相当する
ADF調整飼料区及び水溶性の繊維に相当するヘ
ミセルロース調整飼料区には、貧血の抑制効果が
殆んど認められない。一方、水溶性と水不溶性の
繊維を含むNDF調整飼料区には抑制効果のある
ことが認められる。
以上の実験例の結果から、水溶性と水不溶性の
食物繊維を同時に含む食物繊維である場合に薬物
起因の貧血抑制効果のあることが知れ、この発明
では、かように水溶性と水不溶性の食物繊維の少
なくとも２種類の食物繊維を主成分として含有す
ればよく、これら２種類の食物繊維は、同一種植
物起源のものでも、また２種以上の植物起源のも
のを適宜混合したものでもよい。
植物からのこれら食物繊維の調製方法は特に制
限されるものではなく、公知の手段によつて差し
つかえない。更にこれら２種類の食物繊維を含む
限りは他の物質を存在させても何等支障はない。
この発明の抑制剤は、粉剤、ペレツト剤、顆粒
剤、カプセル剤、錠剤、懸濁剤、乳剤等適宜形態
とすればよく、例えば栄養欠損による貧血治療薬
剤に混合して上記種々形態で用いることができ
る。
（実施例）
水溶性繊維55.4重量％（ヘミセルロース22.0
％、ペクチン19.0％、ガム質14.4％）、水不溶性
繊維26.0重量％（セルロース23.0％、リグニン3.0
％）を含む甜菜より調製した食物繊維（粒度60〜
100メツシユ）２Kgが飼料全体の10％となるよう
にラツト飼育用基本飼料（配合割合カゼイン25
部、コーン油５部、ミネラル混合物４部、ビタミ
ン混合物１部、コリン塩酸塩0.2部、ビタミンＥ
顆粒0.1部、蔗糖54.7部）18Kgに均一に混合した。
別に前記ラツト飼育用基本飼料（但し蔗糖量は
64.7部となる）を対照飼料とし、前記両飼料に
夫々フエナセチン（非ピリン系の解熱鎮痛剤）の
粉末を0.5％添加し、この飼料を５週令のラツト
（雄、平均体重140ｇ）15匹／区に不断給与して、
９週間飼育したところ第３表のようにフエナセチ
ン添加食物繊維混合飼料区では貧血の現象はみら
れなかつた。[Table] According to the results in Table 2, it corresponds to water-insoluble fiber.
Almost no anemia-suppressing effect was observed in the ADF-adjusted feed group and the hemicellulose-adjusted feed group, which corresponds to water-soluble fiber. On the other hand, the NDF-adjusted feed containing water-soluble and water-insoluble fibers was found to have a suppressive effect. From the results of the above experimental examples, it is known that dietary fiber containing both water-soluble and water-insoluble dietary fibers has the effect of suppressing drug-induced anemia. It is sufficient to contain at least two types of dietary fibers as main components, and these two types of dietary fibers may be derived from the same type of plant, or may be an appropriate mixture of two or more types of plant origin. . The method for preparing these dietary fibers from plants is not particularly limited, and any known method may be used. Furthermore, as long as these two types of dietary fibers are included, there is no problem in the presence of other substances. The inhibitor of the present invention may be in any suitable form such as powder, pellet, granule, capsule, tablet, suspension, emulsion, etc. For example, it can be mixed with a drug for treating anemia due to nutritional deficiency and used in the various forms mentioned above. I can do it. (Example) Water-soluble fiber 55.4% by weight (hemicellulose 22.0%
%, pectin 19.0%, gummy 14.4%), water-insoluble fiber 26.0% by weight (cellulose 23.0%, lignin 3.0%)
Dietary fiber prepared from sugar beets (particle size 60~
100 mesh) 2kg is 10% of the total feed (casein ratio: 25%)
part, corn oil 5 parts, mineral mixture 4 parts, vitamin mixture 1 part, choline hydrochloride 0.2 parts, vitamin E
(0.1 part of granules, 54.7 parts of sucrose) was uniformly mixed into 18 kg. Separately, the basic feed for raising rats (however, the amount of sucrose is
64.7 parts) was used as a control feed, and 0.5% of phenacetin (non-pyrine antipyretic analgesic) powder was added to each of the above feeds, and this feed was fed to 15 5-week-old rats (male, average weight 140 g)/ Provide constant salary to the ward,
After 9 weeks of rearing, as shown in Table 3, no anemia phenomenon was observed in the phenacetin-added dietary fiber mixed feed group.
【表】
（効 果）
この発明の貧血抑制物質は無害で、物質自体に
よる副作用の併発がなく、薬物起因の貧血を効果
的に抑制できるので、従来有効な予防法、治療法
がなかつた薬物起因の貧血の改善に寄与するとこ
ろ大である。[Table] (Effects) The anemia-suppressing substance of this invention is harmless, has no side effects from the substance itself, and can effectively suppress drug-induced anemia. It greatly contributes to improving the anemia caused by the disease.
Claims (1)
る食物繊維を有効成分とする薬物起因の貧血抑制
剤。 ２ 食物繊維が甜菜から調製された食物繊維であ
る特許請求の範囲第１項記載の薬物起因の貧血抑
制剤。 ３ 食物繊維が甜菜から調製された食物繊維の中
性消化画分である特許請求の範囲第１項記載の薬
物起因の貧血抑制剤。[Scope of Claims] 1. A drug-induced anemia suppressant whose active ingredient is dietary fiber containing water-soluble dietary fiber and insoluble dietary fiber. 2. The agent for suppressing drug-induced anemia according to claim 1, wherein the dietary fiber is dietary fiber prepared from sugar beet. 3. The drug-induced anemia suppressant according to claim 1, wherein the dietary fiber is a neutrally digested fraction of dietary fiber prepared from sugar beet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60189405A JPS6251623A (en) | 1985-08-30 | 1985-08-30 | Inhibitor for anemia caused by chemical |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60189405A JPS6251623A (en) | 1985-08-30 | 1985-08-30 | Inhibitor for anemia caused by chemical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6251623A JPS6251623A (en) | 1987-03-06 |
| JPH046685B2 true JPH046685B2 (en) | 1992-02-06 |
Family
ID=16240730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60189405A Granted JPS6251623A (en) | 1985-08-30 | 1985-08-30 | Inhibitor for anemia caused by chemical |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6251623A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0779663B2 (en) * | 1990-08-27 | 1995-08-30 | 日本甜菜製糖株式会社 | Porridge dietary fiber and its enhanced food |
| US7072443B2 (en) * | 2002-10-03 | 2006-07-04 | Schick Technologies, Inc. | Intraoral image sensor |
-
1985
- 1985-08-30 JP JP60189405A patent/JPS6251623A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6251623A (en) | 1987-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19732903A1 (en) | Pellet formulation for the treatment of the intestinal tract | |
| EP1194044B1 (en) | Pharmaceutical or dietetic mushroom-based compositions and their use | |
| EP0179819B1 (en) | Stabilized mussel preparation | |
| DE3319575C2 (en) | ||
| DE60002484T2 (en) | COMPOSITION THAT CONTAINS AN ALPHA AMYLASE INHIBITOR AND AT LEAST ONE PHYSIOLOGICALLY ACCEPTABLE COMPONENT THAT CAN REDUCE THE INTESTINAL ABSORPTION OF "FAST SUGARS" | |
| JPS6313967B2 (en) | ||
| DE2921852A1 (en) | LIPID LOWERING AGENT | |
| JPH046685B2 (en) | ||
| DE2259646C2 (en) | High-dose tablets of cephalosporin derivatives, as well as processes for their manufacture | |
| JPH0499728A (en) | Composition having anti-inflammatory action | |
| AU2018348892B2 (en) | Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof | |
| EP3534915B1 (en) | Gamma-polyglutamic acid and zinc compositions | |
| CN113143962B (en) | A pharmaceutical composition for treating hyperlipidemia, and its preparation method | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| US20170368115A1 (en) | Compositions containing curcumin having improved bioavailability | |
| CN108815514B (en) | A hirudin tannate tablet and its preparation method | |
| JPS63216822A (en) | Improving substance for lipid metabolism | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| JP3522186B2 (en) | Propolis preparation and method for producing the same | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
| WO1992022305A1 (en) | Therapeutic composition for sustained release of magnesium | |
| KR20200132261A (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| DE2157201B2 (en) | Improved solid oral administration form of Raubasin | |
| JP2020143037A (en) | Therapeutic pharmaceutical composition for heart failure associated with diabetes | |
| EP0129822A2 (en) | Pharmaceutical preparation with an anti-tumour activity |